menu
    • menu
    [{"orgOrder":0,"company":"Virion Therapeutics","sponsor":"Center for Breakthrough Medicines","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Virion Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Virion Therapeutics \/ Virion Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Virion Therapeutics \/ Virion Therapeutics"},{"orgOrder":0,"company":"Virion Therapeutics","sponsor":"Ocean Biomedical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"VRON-0200-AdC6","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Virion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Virion Therapeutics \/ Virion Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Virion Therapeutics \/ Virion Therapeutics"},{"orgOrder":0,"company":"Virion Therapeutics","sponsor":"Ocean Biomedical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"VRON-0200","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Virion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Virion Therapeutics \/ Virion Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Virion Therapeutics \/ Virion Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Virion Therapeutics

    Menu

    Virion Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Virion Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Virion Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VRON-0200

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Recipient : Ocean Biomedical

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ocean Biomedical (NASDAQ: OCEA) Announces First Patients Dosed by Joint Venture Partner Virion Therapeutics in...

                            Details : VRON-0200, a first-in-class treatment, using one of Virion’s proprietary checkpoint modifiers, was specifically designed to enhance and broaden a patient’s own immune response, which is investigated for Chronic Hepatitis B Virus Infection.

                            Brand Name : VRON-0200

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            October 26, 2023

                            Lead Product(s) : VRON-0200

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Recipient : Ocean Biomedical

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Virion Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Virion Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VRON-0200-AdC6

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Recipient : Ocean Biomedical

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Ocean Biomedical and Virion Therapeutics Form Joint Venture Supporting Multi-National, First-In-Humans Clinica...

                            Details : Companies have entered into a joint venture to accelerate and expand Virion’s clinical-stage program VRON-0200 (VRON-0200-AdC6 vaccine) and pipeline, with the goal of finding cures for patients with chronic hepatitis B and other chronic infectious dise...

                            Brand Name : VRON-0200

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            October 12, 2023

                            Lead Product(s) : VRON-0200-AdC6

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Recipient : Ocean Biomedical

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Virion Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Virion Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VRON-0200,Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : IND Enabling

                            Recipient : Center for Breakthrough Medicines

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Center for Breakthrough Medicines and Virion Therapeutics Announce Strategic Partnership to Manufacture Virion...

                            Details : Under the terms of the collaboration, CBM will manufacture and partner with Virion on their checkpoint modifier clinical development programs, including the First-in-Human VRON-0200 immunotherapy for patients with chronic Hepatitis B Virus (HBV) infectio...

                            Brand Name : VRON-0200

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            February 22, 2023

                            Lead Product(s) : VRON-0200,Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : IND Enabling

                            Recipient : Center for Breakthrough Medicines

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth